Second Genome Appoints Anupama S. Hoey as Chief Business Officer

July 23, 2018, South San Francisco, July 23, 2018

Second Genome, Inc., a leader in the development of novel therapeutics derived from the human microbiome, today announced the appointment of Anupama S. Hoey as chief business officer. In her role, Ms. Hoey will be leading all corporate development activities and strategic alliance opportunities for the company. “Anu joins our team at a pivotal time of growth, with our clinical pipeline growing this year as SGM-1019 moves into a Phase 2 study in nonalcoholic steatohepatitis (NASH) and a second program in inflammatory bowel disease (IBD) enters the clinic,” said Glenn Nedwin, Ph.D., MoT, president and chief executive officer of Second Genome. “As our research continues to yield new therapeutic programs in additional disease areas, such as cancer, metabolic disease and neurological conditions, Anu’s expertise in executing business transactions for promising treatments will be valuable to find the right partners for our pipeline.”

Ms. Hoey is an industry leader with more than 15 years of experience driving business transactions, corporate strategy, leadership team development, corporate governance, and drug discovery R&D. Prior to joining Second Genome, Ms. Hoey served as the chief business officer at Invenra, Inc., where she successfully executed multiple high-profile deals with pharmaceutical companies and leading academic institutions. Before that, she served as vice president of business development at Arcus Biosciences, and as senior director of business development at Sutro Biopharma. Ms. Hoey earned a master of business administration degree from the University of San Francisco, a master of science degree in molecular virology and genetics from Case Western Reserve University, and a bachelor’s degree from Ohio State University.

“Second Genome is transforming the way we think about leveraging the microbiome to treat disease, and has a strong pipeline with the potential to offer innovative and beneficial treatments to patients,” said Ms. Hoey. “I’m excited to join such an experienced management team at Second Genome and look forward to leveraging my expertise to help propel the organization at such a momentous time of growth.”

About Second Genome

Second Genome is a clinical-stage biopharmaceutical company developing innovative therapies derived from the human microbiome. Second Genome’s mission is to transform lives with protein, peptide and/or metabolite therapeutics for human disease. Second Genome has built a novel platform for microbiome drug discovery, which includes one of the world’s largest, dynamic, curated and organized digital database of microbes correlated to metadata, using both proprietary and published data. The team has completed more than 400 microbiome studies, analyzing more than 75,000 samples, for internal R&D, as well as for external partners across government, academia, pharmaceutical, nutrition and industrial companies. The company leverages its microbiome analysis platform along with its biology and clinical expertise to generate insightful findings that can accelerate unique development programs, by elucidating the role of the microbiome in human health conditions. In 2018, Second Genome is advancing its lead program, SGM- 1019, into a Phase 2 clinical trial in NASH, and plans to file an IND for its second clinical candidate, SG-2-0776.

Please visit for more information.

Media Contact

Ian Stone

Canale Communications